Daiichi Sankyo Company (4568) Aktienübersicht
Daiichi Sankyo Company, Limited produziert und vertreibt pharmazeutische Produkte in Japan, Nordamerika, Europa und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 4/6 |
4568 Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Daiichi Sankyo Company, Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | JP¥2,799.50 |
| 52-Wochen-Hoch | JP¥4,178.00 |
| 52-Wochen-Tief | JP¥2,390.00 |
| Beta | -0.16 |
| 1 Monat Veränderung | 10.81% |
| 3 Monate Veränderung | 12.02% |
| 1 Jahr Veränderung | -22.88% |
| 3 Jahre Veränderung | -31.97% |
| 5 Jahre Veränderung | 29.64% |
| Veränderung seit IPO | 262.79% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 14
4568: Tumor Agnostic Oncology Approvals In Europe Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for Daiichi Sankyo Company, cutting the implied price target from ¥6,000 to ¥5,500 as they reassess expectations for revenue growth, profit margins, and the appropriate future P/E multiple. What's in the News AstraZeneca and Daiichi Sankyo secured European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.
Narrative-Update • Jun 30
4568: Broad Oncology Approvals Will Support A Balanced Future Market Rating
Analysts have reduced their Daiichi Sankyo Company price target from ¥2,846.48 to ¥2,750.00, citing updated assumptions that combine slightly higher expected revenue growth with a lower profit margin outlook and a higher future P/E multiple. What's in the News for Daiichi Sankyo Company AstraZeneca and Daiichi Sankyo received European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.Recent updates
Narrative-Update • Jul 14
4568: Tumor Agnostic Oncology Approvals In Europe Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for Daiichi Sankyo Company, cutting the implied price target from ¥6,000 to ¥5,500 as they reassess expectations for revenue growth, profit margins, and the appropriate future P/E multiple. What's in the News AstraZeneca and Daiichi Sankyo secured European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.Narrative-Update • Jun 30
4568: Broad Oncology Approvals Will Support A Balanced Future Market Rating
Analysts have reduced their Daiichi Sankyo Company price target from ¥2,846.48 to ¥2,750.00, citing updated assumptions that combine slightly higher expected revenue growth with a lower profit margin outlook and a higher future P/E multiple. What's in the News for Daiichi Sankyo Company AstraZeneca and Daiichi Sankyo received European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.
Narrative-Update • Jun 16
4568: Oncology Biomarker Advances And Pipeline Approvals Will Drive Future Upside
Analysts have reduced their fair value estimate for Daiichi Sankyo Company from ¥4,736.88 to ¥4,234.71, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News Leica Biosystems expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and AI powered image analysis algorithm for the TROP2 Normalized Membrane Ratio biomarker in non small cell lung cancer, building on AstraZeneca’s computational pathology algorithm and Leica’s digital pathology platform for research use only.Narrative-Update • Jun 01
4568: Oncology Pipeline Progress And Measured Outlook Will Support Future Market Rating
Analysts have trimmed their price target for Daiichi Sankyo Company from about ¥3,065 to around ¥2,846. This reflects updated assumptions for slightly lower revenue growth, a reduced profit margin, a modestly higher discount rate, and a small adjustment to future P/E expectations.Analyseartikel • May 13
Daiichi Sankyo Company, Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
It's been a good week for Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders, because the company has just...Narrative-Update • May 11
4568: Oncology Regulatory Progress In Lung And Breast Cancer Will Drive Upside Potential
Analysts have kept Daiichi Sankyo Company's price target steady at ¥6,000, with small adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions shaping this unchanged view. What's in the News U.S. FDA accepted and granted Priority Review for the Biologics License Application for ifinatamab deruxtecan (I DXd) in extensive stage small cell lung cancer, with an FDA action date set for October 10, 2026.Narrative-Update • Apr 23
4568: Broad Oncology Pipeline And Buyback Progress Will Support A Higher Future Market Rating
Analysts have reduced their price target on Daiichi Sankyo Company from about ¥3,623 to roughly ¥3,065, citing updated assumptions that pair lower expected revenue growth with a slightly higher profit margin outlook and a more restrained future P/E of around 20x. What's in the News The share buyback program was completed, with 31,457,200 shares repurchased for ¥91,846.79 million, representing 1.7% of shares, under the authorization announced on April 25, 2025 (Key Developments).Narrative-Update • Apr 08
4568: Oncology Approvals And Priority Reviews Will Drive Future Upside Potential
Analysts have kept their ¥6,000 price target for Daiichi Sankyo unchanged, citing slightly adjusted views on revenue growth, profit margins, and future P/E assumptions as they refine their outlook on the company. What's in the News ENHERTU (trastuzumab deruxtecan) has been approved in Japan for HER2 positive advanced or recurrent solid cancers that are refractory or intolerant to standard treatments, supported by multiple phase 2 trials and accompanied by an interstitial lung disease warning in the prescribing information (Product related announcements).Narrative-Update • Mar 25
4568: Oncology Pipeline Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target on Daiichi Sankyo Company to ¥4,736.88 from ¥4,949.38, citing slightly lower assumed profit margins and a more conservative future P/E multiple, while keeping core growth assumptions broadly unchanged. What's in the News Daiichi Sankyo and AstraZeneca’s ENHERTU and DATROWAY oncology programs continue to move through global regulators, with multiple supplemental applications and Type II variations under review in the U.S., EU, Japan and China across breast, lung, gastric and other HER2 positive or TROP2 targeted cancer indications (regulatory filings).Narrative-Update • Mar 11
4568: Priority Oncology Filings And Reviews Will Drive Future Upside Potential
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥6,300 to ¥6,000, reflecting slightly lower modeled revenue growth, a modest adjustment to profit margins, and a small uptick in the discount rate and future P/E assumptions in their updated forecasts. What's in the News The U.S. FDA accepted and granted Priority Review to a supplemental Biologics License Application for ENHERTU for certain HER2 positive early breast cancer patients with residual invasive disease after neoadjuvant therapy, with a target decision date of July 7, 2026, under Project Orbis (Key Developments).Narrative-Update • Feb 25
4568: Future Breast Cancer Franchise Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥5,546 to ¥4,949, reflecting slightly lower forecasts for revenue growth, profit margins, and future P/E multiples. What's in the News The Board of Directors of IHH Healthcare Berhad reported that NTK has filed a petition with the Tokyo District Court to amend its claims against Daiichi Sankyo, seeking to adjust an existing injunctive request related to alleged obstruction of securities transactions and corporate actions involving Fortis and Malar, while keeping its previously stated monetary and reputational reliefs unchanged (Lawsuits & Legal Issues).Narrative-Update • Feb 10
4568: Broad Oncology Pipeline Progress Will Support A Higher Future Market Rating
Analysts have lowered their price target on Daiichi Sankyo Company from ¥4,500 to about ¥3,623, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News ENHERTU received multiple regulatory milestones, including approvals in China for HER2 positive metastatic gastric cancer and for HR positive, HER2 low or ultralow metastatic breast cancer, plus U.S. Breakthrough Therapy Designation in HER2 positive early breast cancer with high recurrence risk (company announcements).Analyseartikel • Feb 08
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend of ¥39.00 per share on the 24th...Analyseartikel • Feb 06
There May Be Underlying Issues With The Quality Of Daiichi Sankyo Company's (TSE:4568) Earnings
Daiichi Sankyo Company, Limited's ( TSE:4568 ) robust earnings report didn't manage to move the market for its stock...Analyseartikel • Feb 02
Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders are probably feeling a little disappointed, since its shares...Narrative-Update • Jan 26
4568: Oncology Approvals And Trials Will Drive Future Upside Potential
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300. This reflects only small model adjustments to revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the shares.Analyseartikel • Jan 23
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...Narrative-Update • Jan 12
4568: Expanding Oncology Pipeline And Legal Win Will Drive Future Upside
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300, citing only small adjustments to revenue growth, profit margin, and future P/E expectations, which supports maintaining the prior valuation view. What's in the News ENHERTU received multiple regulatory approvals and designations across the U.S., China, Canada and Europe for various HER2 positive, HER2 low and HER2 ultralow breast cancer settings, including first line metastatic treatment and early stage high risk neoadjuvant use, backed by phase 3 data from DESTINY-Breast06, DESTINY-Breast09 and DESTINY-Breast11 (Key Developments).Analyseartikel • Jan 09
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) will pay a dividend of ¥39.00 on the 24th of June. The payment will take...Narrative-Update • Dec 27
4568: Oncology Pipeline Progress And IP Resolution Will Drive Future Upside
Analysts have nudged their price target for Daiichi Sankyo Company to ¥6,300, reflecting slightly stronger expectations for revenue growth to about 24.0 percent and a marginally higher profit margin near 21.0 percent, while maintaining a broadly similar outlook for valuation multiples. What's in the News ENHERTU received U.S. Breakthrough Therapy Designation for high risk HER2 positive early breast cancer with residual disease after neoadjuvant treatment, supported by positive phase 3 DESTINY Breast05 data and publication in The New England Journal of Medicine (Key Developments).Analyseartikel • Dec 25
Daiichi Sankyo Company (TSE:4568) Will Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...Narrative-Update • Dec 13
4568: Expanding Oncology Pipeline And Legal Clarity Will Drive Future Upside
Analysts have trimmed their price target on Daiichi Sankyo Company from ¥6,800 to ¥6,300. This reflects updated assumptions that pair slightly higher forecast revenue growth and profit margins with a more conservative valuation multiple and discount rate.Analyseartikel • Dec 11
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited's ( TSE:4568 ) investors are due to receive a payment of ¥39.00 per share on 24th of...Narrative-Update • Nov 25
4568: Future Oncology Pipeline Success Will Drive Further Upside For Shares
Analysts have raised their price target for Daiichi Sankyo Company from ¥5,517.06 to ¥5,546.47, citing slightly higher revenue growth expectations. This increase offsets a modest rise in the discount rate and a marginal dip in projected profit margins.Analyseartikel • Nov 04
Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) defied analyst predictions to release its half-yearly results, which were...Narrative-Update • Oct 22
Analysts Lower Daiichi Sankyo Price Target as New Cancer Data Drives Valuation Tweaks
Narrative Update on Daiichi Sankyo Company: Analyst Price Target Adjustment Analysts have slightly reduced their fair value estimate for Daiichi Sankyo Company from ¥5,528.82 to ¥5,517.06. This adjustment reflects moderately revised assumptions around revenue growth and future earnings expectations.Narrative-Update • Oct 08
Global Aging And ADC Pipelines Will Expand Oncology Markets
Analysts have slightly raised their price target for Daiichi Sankyo Company from ¥5,459 to ¥5,529, attributing the adjustment to improved profit margin expectations. This change comes even as revenue growth projections were moderated.Analyseartikel • Sep 21
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be paying its dividend of ¥39.00...Analyseartikel • Sep 05
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...Narrative-Update • Sep 04
Global Aging And ADC Pipelines Will Expand Oncology Markets
With Daiichi Sankyo's net profit margin and future P/E multiples both effectively unchanged, analysts have maintained their consensus price target at ¥5459. What's in the News DATROWAY (datopotamab deruxtecan) approved in China for HR positive, HER2 negative breast cancer after prior endocrine and chemotherapy, jointly developed with AstraZeneca.Analyseartikel • Aug 22
Daiichi Sankyo Company (TSE:4568) Has Announced That It Will Be Increasing Its Dividend To ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...Analyseartikel • Aug 07
Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) will increase its dividend from last year's comparable payment on the 10th...Analyseartikel • Aug 03
Earnings Beat: Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Daiichi Sankyo Company, Limited ( TSE:4568 ) investors will be delighted, with the company turning in some strong...Aktionärsrenditen
| 4568 | JP Pharmaceuticals | JP Markt | |
|---|---|---|---|
| 7D | 0.3% | 1.2% | 2.1% |
| 1Y | -22.9% | 12.6% | 35.2% |
Rendite im Vergleich zur Industrie: 4568 unter dem Niveau der Branche JP Pharmaceuticals , die im vergangenen Jahr eine Rendite von 12.6% erzielte.
Rendite vs. Markt: 4568 hinter dem Markt JP zurück, der im vergangenen Jahr eine Rendite von 35.2 erzielte.
Preisvolatilität
| 4568 volatility | |
|---|---|
| 4568 Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 2.1% |
Stabiler Aktienkurs: 4568 hatte in den letzten 3 Monaten im Vergleich zum JP -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 4568Die wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1899 | 20,171 | Hiroyuki Okuzawa | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited produziert und vertreibt pharmazeutische Produkte in Japan, Nordamerika, Europa und international. Das Unternehmen bietet Enhertu zur Behandlung von Patienten mit HER2-positivem und niedriggradigem Brustkrebs, HER2-positivem Adenokarzinom des Magens oder der gastroösophagealen Verbindungsstelle und HER2-positiven soliden Tumoren an; Turalio, ein oral zu verabreichendes kleines Molekül, das auf den Rezeptor des koloniestimulierenden Faktors 1, die proto-onkogene Rezeptor-Tyrosinkinase KIT und die FMS-ähnliche Tyrosinkinase 3 mit einer internen Tandem-Duplikationsmutation abzielt; Vanflyta, ein FLT3-Inhibitor zur Behandlung erwachsener Patienten mit akuter myeloischer Leukämie; und Injectafer, eine Eisencarboxymaltose-Injektion zur Behandlung von Eisenmangel. Darüber hinaus bietet das Unternehmen Liziana und Savaysa, direkte Faktor-Xa-Inhibitoren, die Blutdrucksenker Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar und Sevikar HCT, Nilemdo, eine orale Behandlung zur Senkung des Cholesterinspiegels, Nustendi, eine fest dosierte Kombinationstablette aus Bempedosäure und Ezetimib zur Senkung des Cholesterinspiegels, sowie Efient, ein Mittel gegen Blutplättchen.
Daiichi Sankyo Company, Limited's Grundlagenzusammenfassung
| 4568 grundlegende Statistiken | |
|---|---|
| Marktanteil | JP¥5.01t |
| Gewinn(TTM) | JP¥259.87b |
| Umsatz(TTM) | JP¥2.12t |
19.3x
Kurs-Gewinn-Verhältnis 2.4x
Kurs-Umsatz-VerhältnisIst 4568 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 4568 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | JP¥2.12t |
| Kosten der Einnahmen | JP¥669.05b |
| Bruttogewinn | JP¥1.45t |
| Sonstige Ausgaben | JP¥1.19t |
| Gewinn | JP¥259.87b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Jul 31, 2026
| Gewinn per Aktie (EPS) | 145.32 |
| Bruttomarge | 68.49% |
| Nettogewinnspanne | 12.24% |
| Schulden/Eigenkapital-Verhältnis | 18.1% |
Wie hat sich 4568 auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
3.6%
Aktuelle Dividendenrendite56%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/24 18:21 |
| Aktienkurs zum Tagesende | 2026/07/24 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Daiichi Sankyo Company, Limited wird von 28 Analysten beobachtet. 17 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |